Tag: NRL-1049

In an experimental research using the ROCK inhibitor NRL-1049 to treat cerebral cavernous malformations, Neurelis has started patient dosing.

The Rho kinase (ROCK) inhibitor NRL-1049, a potential treatment for people with cerebral cavernous malformations (CCM), a condition marked by abnormally enlarged capillary cavities in the brain and spinal cord, was dosed in the first two cohorts of the investigational…

Back to top

This will close in 0 seconds

Registration Form


This will close in 0 seconds